Business Description
Q32 Bio Inc
NAICS : 541714
SIC : 2833
ISIN : US7469641051
Total Employee Number:
22Description
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.72 | |||||
Equity-to-Asset | 0.73 | |||||
Debt-to-Equity | 0.3 | |||||
Debt-to-EBITDA | 0.4 | |||||
Interest Coverage | 26.76 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 98.5 | |||||
3-Year FCF Growth Rate | -34.2 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.27 | |||||
9-Day RSI | 56.03 | |||||
14-Day RSI | 57.68 | |||||
3-1 Month Momentum % | 134.95 | |||||
6-1 Month Momentum % | 338.41 | |||||
12-1 Month Momentum % | 943.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.36 | |||||
Quick Ratio | 5.36 | |||||
Cash Ratio | 4.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.5 | |||||
Shareholder Yield % | -3.27 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | 39.84 | |||||
Net Margin % | 61.86 | |||||
EBITDA Margin % | 63.82 | |||||
FCF Margin % | -51.43 | |||||
OCF Margin % | -51.43 | |||||
ROE % | 309.93 | |||||
ROA % | 50.61 | |||||
ROIC % | 130.73 | |||||
3-Year ROIIC % | -114.6 | |||||
ROC (Joel Greenblatt) % | 536.36 | |||||
ROCE % | 63.02 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 4.7 | |||||
PE Ratio without NRI | 4.7 | |||||
PS Ratio | 3.08 | |||||
PB Ratio | 4.14 | |||||
Price-to-Tangible-Book | 4.14 | |||||
EV-to-EBIT | 5.34 | |||||
EV-to-Forward-EBIT | -5.45 | |||||
EV-to-EBITDA | 5.29 | |||||
EV-to-Forward-EBITDA | -5.45 | |||||
EV-to-Revenue | 3.37 | |||||
EV-to-FCF | -6.77 | |||||
Price-to-Graham-Number | 0.93 | |||||
| Price-to-Net-Current-Asset-Value | 4.82 | |||||
| Price-to-Net-Cash | 5.75 | |||||
Earnings Yield (Greenblatt) % | 18.71 | |||||
FCF Yield % | -12.54 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Q32 Bio Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 45.891 | ||
| EPS (TTM) (€) | 2.368 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 128.82 | ||
| 14-Day RSI | 57.68 | ||
| 14-Day ATR (€) | 0.596743 | ||
| 20-Day SMA (€) | 10.841 | ||
| 12-1 Month Momentum % | 943.1 | ||
| 52-Week Range (€) | 1.1 - 12.55 | ||
| Shares Outstanding (Mil) | 16.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Q32 Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Q32 Bio Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 30 days | ||
| General meeting for 2025 | 2026-06-12 08:30 | 11.14 (+0.54%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 4.20 (+0.00%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-15 12:45 | 4.50 (+0.00%) | ||
| Annual report for 2025 | 2026-03-10 | 3.64 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 3.64 (+0.00%) | ||
| Oppenheimer 36th Annual Healthcare Life Sciences Conference | 2026-02-25 14:00 | 3.78 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 2.12 (+0.00%) | ||
| Guidance call for 2025 | 2025-09-04 15:45 | 1.41 (+0.00%) |
Show
Entries
Q32 Bio Inc Frequently Asked Questions
What is Q32 Bio Inc(FRA:DB0)'s stock price today?
The current price of FRA:DB0 is €11.33. The 52 week high of FRA:DB0 is €12.55 and 52 week low is €1.10.
When is next earnings date of Q32 Bio Inc(FRA:DB0)?
The next earnings date of Q32 Bio Inc(FRA:DB0) is 2026-08-06 Est..
Does Q32 Bio Inc(FRA:DB0) pay dividends? If so, how much?
Q32 Bio Inc(FRA:DB0) does not pay dividend.
Press Release
Articles on Q32 Bio Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers